Insight Molecular Diagnostics has submitted its GraftAssureDx kidney transplant rejection test for FDA review, marking a major milestone after 12 years of development. The company reported Q4 2025 revenues of $1.1 million and completed a $26 million financing to support expansion into heart transplant testing and commercialization efforts. Favorable head-to-head studies support the test's reliability, and regulatory approval is expected in 2026, positioning the company to lead in a $2 billion transplant testing market. The firm aims to scale sales, obtain UK and EU approvals, and advance research in 2026.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Solana (SOL) has gained about 30% from its June low, trading around $78 and surpassing its 50-day EMA. The token's upward momentum is supported by increased speculative trading and a new SuperTrend buy signal, the first since October 2025. However, i...
Kenmare Resources reported weaker-than-expected production in the first half of 2026 due to commissioning delays at its Wet Concentrator Plant A, with ilmenite output down 40% year on year in Q2. Despite this, shipments increased by 53% as the compan...
Ramsdens Holdings PLC shares rose 13.6% to 670p following an improved takeover offer from US pawnbroking group FirstCash. FirstCash increased its cash bid to 675p per share from 600p, raising the total offer value to up to £232 million, including div...
Alphamin Resources delivers strong free cash flow from its high-grade Bisie tin mine, maintaining consistent output of 20,000 tonnes per annum. Despite operational risks in the Democratic Republic of Congo, the company trades at a significant valuati...
